Global Transcatheter Mitral Valve Replacement (TMVR) Market: 2017-2022 Edition
Scope of the Report
The report entitled “Global Transcatheter Mitral Valve Replacement (TMVR) Market: 2017-2022 Edition”, provides analysis of the global TMVR market, with detailed analysis of market size and growth, penetration, market share and economic impact of the industry. The analysis includes the market by value, by volume, by segments and by penetration.
The report also includes the detailed analysis of the regional TMVR market of the following regions: The US and Europe. The analysis in this segment is done by penetration, by segments, by value and by volume.
Growth of the overall global TMVR market has also been forecasted for the years 2017-2022, taking into consideration the previous growth patterns, the growth drivers and the current and future trends. Edward Lifesciences, Medtronic, and Abbott Laboratories are some of the key players operating in the global TMVR market, whose company profiling has been done in the report. In this segment of the report, business overview, financial overview and business strategies of the companies are provided.
Edward Lifescience Incorporation
The mitral valve allows the passage to oxygenated blood from lest atrium (LA) to the left ventricle (LV) and prevent the backflow of blood back into the left atrium. Mitral Regurgitation (MR) is a valve disorder where during heart contraction, blood leaks backward through the mitral valve. This reduces the amount of blood pumped through the body, which leads to declining heart function and heart failure, over the time.
The causes of MR disease are congenital heart disorder, rheumatic fever, trauma, any other heart disease, radiation therapy, etc. The treatments available for MR disease are surgical repair, drug treatment and replacement. There are two types of MR: Degenerative MR (DMR) and Functional MR (FMR). The DMR and FMR can further be subdivided into many types.
There are different approaches for replacement surgery, depending upon the type of MR disease. The TMVR market is in very early stage at this moment, with many companies developing their TMVR devices. The commercial TMVR devices are expected to be launched in next 2-3 years.
Currently, the global TMVR market is in early stage, but is expected to increase at high growth rates during the forecasted period (2017-2022). The global TMVR market is supported by various growth drivers, such as aging population, high number of cases of congenital heart defects, rheumatic fever, low survival rate of surgical repair in FMR patients, etc. Yet, the market faces certain challenges, such as, complexity in design, success of repair surgery in DMR patients, high number of patients not referred for surgery, etc.